Market revenue in 2023 | USD 23.0 million |
Market revenue in 2030 | USD 52.7 million |
Growth rate | 12.6% (CAGR from 2023 to 2030) |
Largest segment | Alzheimer's disease |
Fastest growing segment | Alzheimer's Disease |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Alzheimer's Disease, Parkinson's Disease, Multiple Sclerosis, Autism Spectrum Disorder |
Key market players worldwide | Qiagen NV, Abbott Laboratories, Merck & Co Inc, Johnson & Johnson, Thermo Fisher Scientific Inc, Bio-Rad Laboratories Inc, Sysmex Corp, Merck KGaA, Roche Holding AG, Nimble Therapeutics |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to immunoassay for neurological biomarkers market will help companies and investors design strategic landscapes.
Alzheimer's disease was the largest segment with a revenue share of 36.09% in 2023. Horizon Databook has segmented the Norway immunoassay for neurological biomarkers market based on alzheimer's disease, parkinson's disease, multiple sclerosis, autism spectrum disorder covering the revenue growth of each sub-segment from 2018 to 2030.
Leading clinical professionals and academic researchers in the field have collaborated on its development, along with important Norwegian and worldwide partners. For instance, in December 2022, the Michael J.
Fox Foundation awarded USD 300,000 in grants and public money to scientist Charalampos Tzoulis as part of the “Biomarkers to Support Therapeutic Trials Program” for R&D of novel biomarkers for Parkinson’s disease.
Furthermore, in March 2021, the Neuro-SysMed Research School (RSTN) was established at NeuroSysMed. The establishment of such educational institutions is expected to create demand for immunoassays for neurological biomarkers for R&D purpose of researchers, thereby driving the market growth.
Horizon Databook provides a detailed overview of country-level data and insights on the Norway immunoassay for neurological biomarkers market , including forecasts for subscribers. This country databook contains high-level insights into Norway immunoassay for neurological biomarkers market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account